1 / 16

Epstein Barr Virus in Immunosuppressed Host

Epstein Barr Virus in Immunosuppressed Host. Epstein Barr Virus. = Human herpesvirus 4 Infects more than 95% of the world's population. Humans are the only known reservoir of Epstein-Barr virus. EBV is present in oropharyngeal secretions and is most commonly transmitted through saliva.

salvatore-phelan
Télécharger la présentation

Epstein Barr Virus in Immunosuppressed Host

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Epstein Barr Virus in Immunosuppressed Host

  2. Epstein Barr Virus • = Human herpesvirus 4 • Infects more than 95% of the world's population. • Humans are the only known reservoir of Epstein-Barr virus. • EBV is present in oropharyngeal secretions and is most commonly transmitted through saliva. • The virus replicates in nasopharyngeal epithelial cells. • Viral replication  viremia  lymphoreticular system, including the liver, spleen, and B lymphocytes in peripheral blood. • Host immune response to the viral infection includes activation of CD8+ T lymphocytes • = atypical lymphocytes found in the peripheral blood. • The T lymphocytes kill EBV-infected B cells and eventually reduce the number of Epstein-Barr virus–infected B lymphocytes to less than 1 per 106 circulating B cells. • Latent viral infection of memory B cells

  3. Clinical Manifestations • Most commonly associated with infectious mononucleosis • Classically affects adolescents and young adults • Children often asymptomatic • Self-limited course • Classic triad of symptoms

  4. Sore throat +/- tonsillar Exudate (85% of pts) Lymphadenopathy (usually posterior cervical chain) Present in ~100% of pts

  5. Fever! – 98% of pts ** e.g. Saturday Night Fever

  6. Splenomegaly – seen in 50% pts

  7. Rash! • Generalized maculopapular, urticarial or petechial rash • Erythema nodosum has been reported, but is rare • Rash more common in pts treated with antibiotics (esp. ampicillin or amoxicillin)

  8. Reactive Lymphocytes! • Lymphocytosis = most common lab finding • Absolute count > 4500 • Differential count > 50% • Most pt’s have >10% atypical lymphocytes on peripheral smear • = CD8+ Tcells

  9. Less common manifestations of EBV “EBV can affect virtually any organ.” • Hepatitis Fulminant liver failure • Jaundice is rare • Glomerulonephritis/ Acute Kidney Injury • Pneumonia/Pleural effusion • Myocarditis • Pancreatitis • Myositis

  10. Hepatitis! Increased infiltration by CD8+ T cells  Inflammation of the liver  Transaminitis

  11. Neurologic syndromes • Guillian-Barre • Cranial nerve palsies • Encephalitis • Aseptic meningitis • Transverse myelitis • Optic neuritis

  12. Oral Hairy Leukoplakia! Vs. Oral Candidiasis

  13. Epstein-Barr virus serology • Antibodies to Epstein-Barr virus antigens • Antibodies to viral capsid antigen (VCA), • early antigens (EAs) • Epstein-Barr nuclear antigen (EBNA). • Primary acute Epstein-Barr virus infection is associated with VCA-IgM, VCA-IgG, and absent EBNA antibodies. • The antibody pattern in recent infection (3-12 mo) includes positive findings for VCA-IgG and EBNA antibodies, negative VCA-IgM antibodies, and, usually, positive EA antibodies. • Patients who are immunocompromised and have persistent or reactivated Epstein-Barr virus infections often have high levels of antibodies to EA/D or EA/R.

  14. Monospot • Rapid slide agglutination tests, including Monospot assays, have been developed to measure acute infectious mononucleosis heterophile antibodies in a rapid qualitative fashion. Slide tests use either horse RBCs or bovine RBCs. • All commercial kits for rapid diagnosis of acute infectious mononucleosis heterophile antibodies have low sensitivity (63-84%), with a negative predictive value of more than 10%. • Spot tests rarely yield false-positive results in patients with lymphoma or hepatitis.

  15. Treatment • In most cases, no treatment is necessary ---------------------------------------------------- • Corticosteroids for tonsillar edema / respiratory distress • In vitro trials of acyclovir • Our patient was treated with Valcyte 900mg po q day • IVIG for immune-mediated thrombocytopenia

  16. THE END

More Related